- Home
- GITS vs BMRA Comparison
GITS vs BMRA Comparison
Compare GITS & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GITS | BMRA |
|---|---|---|
| Founded | 2018 | 1971 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.6M | 6.3M |
| IPO Year | N/A | 1995 |
Fundamental Metrics
Financial Performance| Metric | GITS | BMRA |
|---|---|---|
| Price | $2.45 | $2.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 151.8K | 8.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $5,311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.66 | $0.40 |
| 52 Week High | $7.09 | $4.60 |
Technical Indicators
Market Signals| Indicator | GITS | BMRA |
|---|---|---|
| Relative Strength Index (RSI) | 50.26 | 35.60 |
| Support Level | $2.13 | N/A |
| Resistance Level | $3.28 | $2.40 |
| Average True Range (ATR) | 0.51 | 0.12 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 32.88 | 39.02 |
Price Performance
Historical ComparisonAbout GITS Global Interactive Technologies Inc.
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.